home / stock / nbrv / nbrv news

NBRV News and Press, Nabriva Therapeutics plc From 10/31/19

Stock Information
Company Name: Nabriva Therapeutics plc
Stock Symbol: NBRV
Market: NASDAQ
Menu
NBRV NBRV Quote NBRV Short NBRV News NBRV Articles NBRV Message Board
Get NBRV Alerts

News, Short Squeeze, Breakout and More Instantly...
NBRV - Nabriva Therapeutics to Report Third-Quarter 2019 Financial Results on November 12, 2019

DUBLIN, Ireland, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third-quarter 201...
NBRV - Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

DUBLIN, Ireland, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that it will present data on the pooled r...

NBRV - Nabriva Therapeutics (NBRV) Presents At Cantor Healthcare Conference - Slideshow

The following slide deck was published by Nabriva Therapeutics plc in conjunction with this Read more ...

NBRV - Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

WASHINGTON , Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven of its member companies will present data from their clinical ...
NBRV - Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical Association

DUBLIN, Ireland, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that the Journal of the American Medica...

NBRV - Key events next week - healthcare

Noteworthy events during the week of September 29 - October 5 for healthcare investors. More news on: Capricor Therapeutics, Inc., Enanta Pharmaceuticals, Inc., ACADIA Pharmaceuticals Inc., Healthcare stocks news, , Read more ...

NBRV - Nabriva to Present Data from XENLETA (lefamulin) and CONTEPO (fosfomycin) Development Programs at IDWeek 2019

DUBLIN, Ireland, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that data from its XENLETA™ (lefa...
NBRV - The Lowdown On Nabriva

Great minds with great ideas usually share in the midst of their persecution " - Jeremy Aldana Today, we look at a small antibiotic concern. This 'busted IPO' comes from across the pond and recently received FDA approval for its primary drug candidate. We provide an in-depth 'deep dive' i...

NBRV - Nabriva Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Exec...

NBRV - Nabriva's XENLETA(TM) (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.

DUBLIN, Ireland, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that the oral and intravenous (IV) formu...
Previous 10 Next 10